Phase I Trials of Ormaplatin (NSC 363812)

Tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum (IV), ormaplatin (OP), NSC 363812, formerly called tetraplatin, is a second generation platinum (IV) compound which has been evaluated in clinical trials sponsored by the National Cancer Institute (NCI) in collaboration with Upjohn. Interest in this group of compounds was stimulated by structure-activity studies by Burchenal et al.,(1) which suggested that platinum compounds containing the 1,2-diaminocyclohexane (DACH) carrier ligand retained activity in vitro and in vivo against L1210 and P388 murine leukemia cell lines with acquired resistance to cisplatin. In addition, in preclinical antitumor testing, OP demonstrated broad spectrum activity comparable to or superior to cisplatin (CDDP) against a variety of murine and human tumor models (2,3) however, its activity in other models was variable and against a screening panel of 16 human ovarian cancer cell lines was disappointing (4).